We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.37B
AUM Growth
+$113M
Cap. Flow
+$184M
Cap. Flow %
13.39%
Top 10 Hldgs %
57.14%
Holding
78
New
18
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$69.7M
2
ABBV icon
AbbVie
ABBV
+$66.1M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$52.5M
4
SYK icon
Stryker
SYK
+$43M
5
REPL icon
Replimune Group
REPL
+$37.7M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$86.5M
2
ELAN icon
Elanco Animal Health
ELAN
+$51.7M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$19.3M
4
COGT icon
Cogent Biosciences
COGT
+$14.4M
5
INCY icon
Incyte
INCY
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$245M 17.88%
1,550,280
– –
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$118M 8.61%
2,793,987
– –
GILD icon
3
Gilead Sciences
GILD
$161B
$71.5M 5.21%
+774,227
New +$69.7M
ABBV icon
4
AbbVie
ABBV
$458B
$63.9M 4.65%
+359,393
New +$66.1M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$62.1M 4.52%
504,193
+315,631
+167% +$37.2M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.66B
$52.1M 3.8%
+428,771
New +$52.5M
AVBP icon
7
ArriVent BioPharma
AVBP
$1.48B
$45.2M 3.29%
1,696,752
– –
AZN icon
8
AstraZeneca
AZN
$263B
$42.7M 3.11%
325,672
-79,031
-20% -$11.1M
SYK icon
9
Stryker
SYK
$127B
$41.8M 3.04%
+116,005
New +$43M
AXSM icon
10
Axsome Therapeutics
AXSM
$12.4B
$41.6M 3.03%
491,726
+112,199
+30% +$10.3M
REPL icon
11
Replimune Group
REPL
$814M
$38.1M 2.78%
3,149,522
+3,101,384
+6,443% +$37.7M
INCY icon
12
Incyte
INCY
$23.5B
$36.2M 2.64%
524,267
-189,909
-27% -$13.5M
RAPP
13
Rapport Therapeutics
RAPP
$1.95B
$35.4M 2.58%
1,995,594
– –
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$34M 2.48%
757,248
+170,904
+29% +$8.86M
BSX icon
15
Boston Scientific
BSX
$65.8B
$31M 2.25%
346,571
+210,752
+155% +$18.6M
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.41B
$27.5M 2%
1,069,090
-680,365
-39% -$19.3M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$36.3B
$25.9M 1.89%
+110,157
New +$29M
ALKS icon
18
Alkermes
ALKS
$8.82B
$25.7M 1.87%
+894,266
New +$25.7M
DYN icon
19
Dyne Therapeutics
DYN
$4.04B
$25.2M 1.84%
1,071,498
+299,428
+39% +$8.86M
DXCM icon
20
DexCom
DXCM
$27.6B
$22.6M 1.64%
+290,210
New +$21.5M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7B
$22.2M 1.62%
397,428
+120,750
+44% +$6.67M
GMED icon
22
Globus Medical
GMED
$10.4B
$20.2M 1.47%
+244,700
New +$19.3M
ISRG icon
23
Intuitive Surgical
ISRG
$121B
$19.8M 1.44%
+37,896
New +$19.7M
INSM icon
24
Insmed
INSM
$23.2B
$17.7M 1.29%
256,281
-30,026
-10% -$2.16M
YMAB
25
DELISTED
Y-mAbs Therapeutics
YMAB
$17.2M 1.25%
2,194,278
– –
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2024 Portfolio in Review

As of Q4 2024, Sofinnova Investments held 78 positions worth $1.37B, up 9% from $1.26B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $184M of net new capital in Q4 2024, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Gilead Sciences: 774,227 shares worth $71.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $19.3M trimmed.

  • Sofinnova Investments's largest Q4 2024 buy was Gilead Sciences: 774,227 shares worth $71.5M.
  • Sofinnova Investments added most to Replimune Group in Q4 2024, an estimated $37.7M increase.
  • Sofinnova Investments's biggest Q4 2024 reduction was IDEAYA Biosciences, cutting an estimated $19.3M.
  • Sofinnova Investments fully exited Novo Nordisk in Q4 2024, selling an estimated $86.5M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.37B portfolio in Q4 2024.
  • Sofinnova Investments opened 18 new positions and closed 17 in Q4 2024.
  • Sofinnova Investments's portfolio value rose 9% quarter-over-quarter to $1.37B.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.